Navigation Links
New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients
Date:5/5/2011

nally, the majority of patients were taking multiple medications, including antiplatelets (93 percent), cholesterol-lowering drugs (88 percent), blood pressure-lowering drugs (84 percent) and beta-blockers (93 percent).

Study results show a total of 182 adverse cardiovascular events in 89 of a total of 173 patients. A blinded, external endpoint committee reviewed the ischemia-related events, with the correlation between ischemia-related (blood flow to the heart) events and episodes of ST-segment deviations to be presented. The study was stopped early due to the low rate of heart attack among study participants.

"What's interesting about these data is there were virtually no heart events in this group of very sick patients, suggesting their disease was well managed by a combination of medical therapy and revascularization," said Timothy D. Henry, M.D., FSCAI, director of research and an interventional cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital. "Further research is needed to analyze the use of this signaling system within ICDs, as this innovation could open a new window to detecting heart attacks and preventing heart damage and death."

The ST-DETECT Trial was sponsored by Medtronic, Inc.

Dr. Henry will present "The ST-DETECT Trial" in the General Session on Thursday, May 5, 2011, 9:15 a.m. to 9:30 a.m.

About SCAI

Headquartered in Washington, D.C., the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specia
'/>"/>

SOURCE Society for Cardiovascular Angiography and Interventions (SCAI)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource
2. Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp
3. Lexicon to Provide First Quarter 2011 Financial Results
4. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
5. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
6. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
7. China Botanic Pharmaceutical Provides Update on Badger Oil Sales
8. Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
9. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
10. Atrium Provides Grant to Establish Education Web Site at AtriumU.com
11. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... PRINCETON, N.J., Feb. 2, 2011 Eli Lilly and ... Company (NYSE: BMY ) announced today that ... global Phase III studies evaluating necitumumab, an investigational anti-cancer ... lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
... BOTHELL, Wash., Feb. 2, 2011 Cardiac Science Corporation ... ) and diagnostic cardiac monitoring devices, has been ... Flow Control facilities globally. Tyco Flow Control is a $3.4B ... facilities throughout the globe. The first phase of the rollout, ...
Cached Medicine Technology:Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10Tyco Division Awards Global AED Contract to Cardiac Science 2Tyco Division Awards Global AED Contract to Cardiac Science 3Tyco Division Awards Global AED Contract to Cardiac Science 4
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... has announced plans to release a newly redesigned website at Healthpointe.net. The new ... enhanced user experience. , The redesign serves to provide smoother interactions between ...
(Date:7/31/2015)... ... July 31, 2015 , ... ZH Healthcare announces a ... , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare dedicated ... a service (SaaS). , HITaaS manages all aspects of infrastructure, security, ...
(Date:7/31/2015)... ... July 31, 2015 , ... EB ... and Hospital Medicine Practice, is pleased to announce that it has partnered with ... format available on iPhones, iPads, and Android smartphones and tablets. , “The ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... new vaccine called the TAT vaccine has been developed in ... date. And more importantly it has had a 71% success ... for human testing and this may be the brightest hope ... of the Department of Virology at Italy’s National Health Institute ...
... social neglect and being unwanted even by near and dear ... like the other people - wherever they want and whenever ... passengers. Others are just indifferent. Leaving the ethical issues aside, ... of, many reasons. Primarily the physicians of these patients do ...
... The outgoing U.S. president Bill Clinton will be remembered as ... by becoming the first American president in history to be ... to win at the senate did he save himself and ... of many burning controversies throughout his term and his mid ...
... pregnancy can lead to increased risk of heart problems ... environment contribute to several aspects of cardiovascular risks in ... ,People whose mothers starved during the first 13 ... their adult life, Starvation during mid or late pregnancy ...
... cancer is pancreatic cancer, though it isn’t very common. Globally ... is some hope for the unfortunate victims. A new vaccine ... it has increased the survival rates in many. ,Vaccines ... In cancer, however, they are used along with other therapies ...
... new research into how our immunity works says stress reduces ... long we have agreed that stress is bad for our ... is sure to cause a lot of concern. , ... claming many victims every day, the new buzzword is immunity ...
Cached Medicine News:
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: